Phantasmidine Alkaloid Agonists for Nicotinic Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for additional nicotinic acetylcholine receptor agonists, as existing compounds have limitations in treating diseases such as Alzheimer's, tobacco dependence, and glaucoma, and there is a requirement for compounds with altered subtype selectivity.
Innovation Solution
Phantasmidine, a condensed tetracyclic alkaloid isolated from Epipedobates anthonyi, is developed, along with related compounds of Formulas I-XIII, which act as nicotinic acetylcholine receptor agonists, offering altered subtype selectivity and potential therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing nicotinic agonists are used, then therapeutic activity is achieved, but subtype selectivity is insufficient
Solution Approach 1:
The patent modifies specific regions of the epibatidine molecule by substituting hydrogens at particular positions (e.g., 2-fluoro, 6-methoxy groups) to create localized changes that enhance binding affinity for specific nicotinic receptor subtypes while maintaining overall molecular functionality
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types (fluoro, methoxy, chloro groups), substitution positions, and molecular configurations to optimize the balance between therapeutic activity and subtype selectivity across different nicotinic receptor subtypes
2Quantity of substance
If chemical complexity of frog alkaloid extracts is increased, then more active compounds are found, but isolation and characterization difficulty increases
Solution Approach 1:
The patent isolates and characterizes individual alkaloid compounds (epibatidine, N-methylepibatidine, phantasmidine) from complex frog skin extracts, separating the active principles from the mixture to enable precise structure-activity relationship studies and therapeutic development
Solution Approach 2:
The patent divides the complex alkaloid extract into distinct compositional categories (epibatidine congeners, pyrroloiminoquinazolinone derivatives, other alkaloids) and further segments them into individual compounds for separate characterization and evaluation
Data Source
AI summary
The invention provides novel nicotinic acetylcholine receptor agonists, for example, phantasmidine and derivatives thereof, for example a compound of formula I. Also disclosed are methods of treating disorders responsive to nicotinic acetylcholine receptor agonists such as Alzheimer's disease, schizophrenia, Myasthenia Gravis, Tourette's syndrome, Parkinson's disease, epilepsy, pain, and cognitive dysfunction by treatment with the nicotinic acetylcholine receptor agonists.